Ethacrynic Acid

Ethacrynic Acid

SCHEMBL3713733

C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl.Cl

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC12A1

The experimentally established mechanism targets of Ethacrynic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTP1 P09211 14/20 0.97
GSTA1 P08263 8/20 0.97
CYP2C9 P11712 2/20 0.97
ALDH1A1 P00352 2/20 0.97
NPSR1 Q6W5P4 2/20 0.97
MEN1 O00255 1/20 0.97
ABCC3 O15438 1/20 0.97
PLIN1 O60240 1/20 0.97
LMNA P02545 1/20 0.97
TP53 P04637 1/20 0.97
MAPT P10636 1/20 0.97
HSPD1 P10809 1/20 0.97
TSHR P16473 1/20 0.97
HTT P42858 1/20 0.97
RECQL P46063 1/20 0.97
MAP2K6 P52564 1/20 0.97
HSPE1 P61604 1/20 0.97
GSTO1 P78417 1/20 0.97
PLIN5 Q00G26 1/20 0.97
KMT2A Q03164 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethacrynic Acid SCHEMBL26353 0.99 GSTP1 (1.00) GSTP1GSTA1CYP2C9ALDH1A1NPSR1
Ethacrynic Acid SCHEMBL9108011 0.99 GSTP1 (1.00) GSTP1GSTA1CYP2C9ALDH1A1NPSR1
Ethacrynic Acid SCHEMBL29384243 0.99 GSTP1 (1.00) GSTP1GSTA1CYP2C9ALDH1A1NPSR1
Ethacrynic Acid SCHEMBL2482896 0.97 GSTP1 (0.97) GSTP1GSTA1CYP2C9ALDH1A1NPSR1
Ethacrynic Acid SCHEMBL905726 0.97 GSTP1 (0.97) GSTP1GSTA1CYP2C9ALDH1A1NPSR1
Ethacrynic Acid SCHEMBL18263238 0.91 GSTP1 (0.86) GSTP1GSTA1CYP2C9ALDH1A1NPSR1
Ethacrynic Acid SCHEMBL8907134 0.90 GSTP1 (0.84) GSTP1GSTA1CYP2C9ALDH1A1NPSR1
SCHEMBL10543330 0.88 GSTP1 (0.81) GSTP1GSTA1CYP2C9ALDH1A1NPSR1
SCHEMBL10001217 0.88 GSTP1 (0.81) GSTP1GSTA1CYP2C9ALDH1A1NPSR1
SCHEMBL9717560 0.88 GSTP1 (0.80) GSTP1GSTA1CYP2C9ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2016085-B9 TRANSITION METAL COMPLEXES FOR INHIBITING RESISTANCE IN THE TREATMENT OF CANCER AND METASTASIS ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE EPFL (CH) 2015-12-30 EP disclosed
EP-2016085-B1 TRANSITION METAL COMPLEXES FOR INHIBITING RESISTANCE IN THE TREATMENT OF CANCER AND METASTASIS ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE EPFL (CH) 2015-08-05 EP disclosed
US-20150190362-A1 TRANSITION METAL COMPLEXES FOR INHIBITING RESISTANCE IN THE TREATMENT OF CANCER AND METASTASIS ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) 2015-07-09 US disclosed
US-9018199-B2 Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2015-04-28 US disclosed
US-20110306671-A1 AMIDE DERIVATIVES OF ETHACRYNIC ACID The Regents of the The University of California (US) 2011-12-15 US disclosed
WO-2010077310-A2 AMIDE DERIVATIVES OF ETHACRYNIC ACID THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-07-08 WO disclosed
US-20090312301-A1 Transition Metal Complexes for Inhibiting Resistance in the Treatment of Cancer and Metastasis ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2009-12-17 US disclosed
EP-2016085-A1 TRANSITION METAL COMPLEXES FOR INHIBITING RESISTANCE IN THE TREATMENT OF CANCER AND METASTASIS EPFL Ecole Polytechnique Fédérale de Lausanne (CH) 2009-01-21 EP disclosed
WO-2007128158-A1 TRANSITION METAL COMPLEXES FOR INHIBITING RESISTANCE IN THE TREATMENT OF CANCER AND METASTASIS ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150190362-A1 TRANSITION METAL COMPLEXES FOR INHIBITING RESISTANCE IN THE TREATMENT OF CANCER AND METASTASIS SLC39A3, FABP2, APC GSTP1 153/4885GSTA1 209/4885CYP2C9 2659/4885
US-20090312301-A1 Transition Metal Complexes for Inhibiting Resistance in the Treatment of Cancer and Metastasis SLC39A3, FABP2, SLC30A6 GSTP1 84/4885GSTA1 144/4885CYP2C9 1997/4885
US-20110306671-A1 AMIDE DERIVATIVES OF ETHACRYNIC ACID EPX, TNF, NFKBIA GSTP1 492/4885GSTA1 258/4885CYP2C9 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.